Sofinnova Partners is a European venture capital firm focused on life sciences, healthcare, and sustainability. Based in Paris, London, and Milan, the firm manages over €4bn and has backed more than 500 companies since 1972.
Portfolio
5
companies
AUM
£4000M
under management
T-Therapeutics
Developer of next-generation T cell receptor therapeutics for oncology and immunology.
Forth Therapeutics
Forth Therapeutics develops next-generation precision treatments for fibrosis.
Latent Labs
Latent Labs builds AI foundation models to make biology programmable.
Synthace
Synthace provides a cloud platform that enables life scientists to automate experiments and share insights.
Sphere Fluidics
Sphere Fluidics creates advanced single cell analysis systems for biotherapeutic discovery.
Tom Burt
Partner
Thomas Burt
Partner
Graziano Seghezzi
Managing Partner
Edward Kliphuis
Partner
BGF and Tencent join existing shareholders to support the biotechnology company in advancing its drug development programmes.
"We are delighted to have significantly added to our Series A financing, which we see as a strong validation of both our technology and our progress to date. I would like to thank Tencent and BGF for their belief in our potential, as well as all our existing investors for their continued support."
The financing from Sofinnova Partners and Old College Capital will support the launch of precision fibrosis therapeutics.
"Launching Forth Tx through Sofinnova’s biotech accelerator has allowed us to translate years of our multiomics-driven research into precision therapies that we hope will transform patients’ lives. Fibrosis is an area of huge unmet medical need, and I’m delighted to be working with Alex and the Sofinnova team, as well as OCC, to deliver potent, new treatments for patients with fibrosis."
The financing round was co-led by Radical Ventures and Sofinnova Partners to accelerate the development of programmable biology tools.
"Every biotechnology or pharmaceutical company wants to be at the forefront of technology to find the best therapeutic molecules, yet not all are in a position to develop the most advanced AI models for the job. That’s where Latent Labs comes in. We push the frontiers of generative biology, giving our partners instant access to tools that accelerate their drug design programs."
The financing round was led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital.
"We’re delighted to have raised this Series A with such high-quality investors whose amazing networks and shared vision will help us deliver highly differentiated TCR cancer therapies. TCR therapeutics are very much at the dawn of their potential. We intend to replicate the success of therapeutic antibodies but build on this in a new dimension, by using the targeting domains of TCR receptors to take advantage of their much greater specificity for cancer cells compared to normal cells. The same logic can be used to target immunosuppressive biologics to tissues impacted by autoimmune disorders."
The life sciences software provider raised the capital from Horizons Ventures and Sofinnova Partners to fund commercial growth.
"But to maximize impact, we need to expand access and reach to customers across the globe—at scale. This investment serves as a strong vote of confidence from world-class investors in the biopharmaceutical and innovation technology industries. With their support, we’ll be able to better deploy human and financial capital to help transform scientific dreams into drugs and alternative food sources."
The investment round was co-led by Sofinnova Partners and Redmile Group to fund global expansion and research programmes.
"This is a transformational investment from two of the most respected specialist investment funds in the industry and a recognition of the untapped potential of the pioneering product and market development carried out by the Company to date"
